Mitapivat PDUFA Date for Sickle Cell Disease Extended to February 2027

Agios Pharmaceuticals announced the FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027, a 3-month delay. The extension follows a major amendment to the sNDA, which was submitted under accelerated approval. Agios maintains confidence in mitapivat's potential, citing positive RISE UP trial results. The company expects mitapivat to be a significant growth driver.

Original reporting
Published Oct 30, 2026, 1:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Mitapivat PDUFA Date for Sickle Cell Disease Extended to February 2027 — source image
Decision brief

The 30-second read

$AGIOBearishMed
01

Why it matters

Regulatory delay may delay revenue contribution from the new indication, affecting short‑term earnings forecasts.

02

Market read

The news is a primary regulatory update for a biotech firm, likely influencing its stock price in the near term.

03

What to watch

Potential for Agios to leverage existing commercial infrastructure for a faster rollout once approved.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Agios Pharmaceuticals (NASDAQ: AGIO) is developing mitapivat for sickle cell disease, building on its existing PK deficiency product Pyrukynd.

Company-level read

Ticker impact

$AGIOBearishHigh confidence
Context

FDA extended the PDUFA goal date for Agios' mitapivat in sickle cell disease to February 1, 2027, delaying potential market launch.

Expected impact

likely downward pressure as investors reassess near‑term growth expectations

Evidence & confidence

Regulatory delay reduces near‑term upside; the market had anticipated a Q4 2026 decision. No new positive data offset the setback.

Market effects

May temper enthusiasm for biotech stocks awaiting FDA decisions on hematology therapies.

Limited to US biotech sector; no broader regional effect.

Minimal global impact beyond investors tracking FDA pipelines.

Counterpoint

If the extension reflects thorough review, the eventual approval could be more robust, offering upside on a later timeline.

Key entities

  • Agios Pharmaceuticals

    Developer of mitapivat, seeking FDA approval for sickle cell disease indication.

  • FDA

    Extended the PDUFA target date, indicating additional review requirements.

Related articles

$AGIOMed

Agios Earnings Call: AQVESME Growth Meets FDA Uncertainty

Agios Pharmaceuticals (AGIO) reported Q3 revenue of $55.4M, up from $12.9M a year earlier, driven by strong AQVESME adoption. The company saw 177 new prescriptions, with 75% patient persistence. International revenue rose 74% to $6.6M. Agios prepares for a potential sickle cell launch, but faces FDA review extension and higher expenses. Q3 net loss narrowed to $65M from $103M YoY.

$AGIOMed

Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue surged 4x, but faced a 3-month FDA review delay for mitapivat in sickle cell disease, increasing uncertainty. Net loss narrowed to $65M from $103.4M YoY. Selling expenses rose to $56.5M, and no 2027 guidance was provided. Thalassemia launch growth may moderate, with 177 prescriptions as a new run rate. Pipeline programs remain early-stage.

$AGIOMed

Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Agios Pharmaceuticals reported Q3 2026 revenue of $55.4M, driven by mitapivat in thalassemia. The company plans to cut R&D headcount by 35% to focus on rare hematology and aims for non-GAAP profitability in 2028. Mitapivat's sickle cell disease approval was delayed to February 2027 due to FDA review. The company is also advancing AG-236 for polycythemia vera and cevidoplenib for immune thrombocytopenia.

$AGIOMed

Agios (AGIO) Q3 2026 Earnings Call Transcript

Agios (AGIO) reported Q3 2026 earnings, highlighting $55.4M in mitapivat revenue, a 3-month FDA review extension for sickle cell disease, and $907M in cash. The company plans to reduce R&D headcount by 35% and aims for non-GAAP profitability in 2028. Mitapivat saw a 4x revenue increase YoY, with strong U.S. and international demand.

$AGIOHigh

Truist cuts Agios Pharma stock price target on SCD concerns

Truist Securities reduced its price target for Agios Pharmaceuticals (NASDAQ: AGIO) to $35 from $37, citing concerns about sickle cell disease. The stock is currently trading at $28.38, down 15.7% over the past week. Agios reported Q3 2026 earnings that missed expectations, but revenue exceeded estimates. The company announced a 35% reduction in R&D headcount, aiming for non-GAAP profitability in 2028.

$AGIOHigh

Agios Q3 Mitapivat Revenue Surges More Than Fourfold; Sickle Cell FDA Decision Set For February 2027

Agios Pharmaceuticals (AGIO) reported Q3 2026 revenue of $55.4M for mitapivat products, up over fourfold YoY. U.S. revenue rose to $48.7M, while ex-U.S. revenue increased to $6.6M. Net loss narrowed to $65.0M. The FDA extended the PDUFA goal date for mitapivat in sickle cell disease to February 2027. Agios plans to reduce R&D workforce by over 35% by year-end 2026.